BioWorld

May 28, 2004

Acadia, Critical Therapeutics Price In 'Not A Robust Market'

Two more biotech companies went public Thursday, but as has been the case lately, their offerings brought in less than first expected. (BioWorld Today) Read More

With MyVax In Phase III, Genitope Raising $51.8M In Public Offering

Chiron Gains Vaccine Contract Against Avian Influenza Strain

Syrrx Receives Milestone From Biogen Idec In Target Agreement

Holiday Notice

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 19, 2025.

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 19, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Rare earth: Biomarin to use global reach post-$4.8B Amicus buy

BioWorld

Biomarin Pharmaceutical Inc. followed up its May takeover of Inozyme Pharma Inc. with a much larger agreement to acquire Amicus Therapeutics Inc. for $14.50 per...